Bevacizumab (Avastin) has some SAE's amid a blackbox warning. The 60 patient trial suggests end date of 01/28...Butt, given its an open-label randomized trial we'll be able to have a look see...as the trial matures...with the understanding that once effectiveness is determined everyone on the 350 side goes to 700.?
Is that correct?...